644 related articles for article (PubMed ID: 32461141)
1. The case of complement activation in COVID-19 multiorgan impact.
Noris M; Benigni A; Remuzzi G
Kidney Int; 2020 Aug; 98(2):314-322. PubMed ID: 32461141
[TBL] [Abstract][Full Text] [Related]
2. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: Complement, Coagulation, and Collateral Damage.
Lo MW; Kemper C; Woodruff TM
J Immunol; 2020 Sep; 205(6):1488-1495. PubMed ID: 32699160
[TBL] [Abstract][Full Text] [Related]
4. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
5. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
6. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.
Magro C; Mulvey JJ; Berlin D; Nuovo G; Salvatore S; Harp J; Baxter-Stoltzfus A; Laurence J
Transl Res; 2020 Jun; 220():1-13. PubMed ID: 32299776
[TBL] [Abstract][Full Text] [Related]
7. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
Iba T; Connors JM; Levy JH
Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
[TBL] [Abstract][Full Text] [Related]
8. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
9. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
10. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy.
Zhang J; Tecson KM; McCullough PA
Rev Cardiovasc Med; 2020 Sep; 21(3):315-319. PubMed ID: 33070537
[TBL] [Abstract][Full Text] [Related]
11. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
12. SARS-CoV-2 and coagulation disorders in different organs.
Vinayagam S; Sattu K
Life Sci; 2020 Nov; 260():118431. PubMed ID: 32946915
[TBL] [Abstract][Full Text] [Related]
13. COVID-19, microangiopathy, hemostatic activation, and complement.
Song WC; FitzGerald GA
J Clin Invest; 2020 Aug; 130(8):3950-3953. PubMed ID: 32459663
[No Abstract] [Full Text] [Related]
14. Possible mechanisms responsible for acute coronary events in COVID-19.
Sheth AR; Grewal US; Patel HP; Thakkar S; Garikipati S; Gaddam J; Bawa D
Med Hypotheses; 2020 Oct; 143():110125. PubMed ID: 32763657
[TBL] [Abstract][Full Text] [Related]
15. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
16. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
Mustafa MI; Abdelmoneim AH; Mahmoud EM; Makhawi AM
Mediators Inflamm; 2020; 2020():8198963. PubMed ID: 33029105
[TBL] [Abstract][Full Text] [Related]
18. The complement system in COVID-19: friend and foe?
Java A; Apicelli AJ; Liszewski MK; Coler-Reilly A; Atkinson JP; Kim AH; Kulkarni HS
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32554923
[TBL] [Abstract][Full Text] [Related]
19. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection.
Ramlall V; Thangaraj PM; Meydan C; Foox J; Butler D; Kim J; May B; De Freitas JK; Glicksberg BS; Mason CE; Tatonetti NP; Shapira SD
Nat Med; 2020 Oct; 26(10):1609-1615. PubMed ID: 32747830
[TBL] [Abstract][Full Text] [Related]
20. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
